ClinicalTrials.gg
RecruitingNCT05038332Updated Jan 16, 2026

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

A Phase 2 interventional study of Ultra-hypofractionated radiation therapy and Moderately Hypo-fractionated Radiation Therapy in Prostate Cancer, sponsored by University of Michigan Rogel Cancer Center. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by University of Michigan Rogel Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center — 7 open to participants now, 12 under way, none of them phase 3. Prostatic Neoplasms · University of Michigan Rogel Cancer Center.

Planned enrollment
6th of 33
136 · median 28
Started
2021
with 3 others
Phase 2
15 of 36
1 open now
Primary completion
2026-11
later than 2 of 11 live
Registered
27th of 36
by date

Among the 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center, this one is the 6th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2021, is one of 15 in phase 2, reaches primary completion later than 2 of the 11 other live ones, and was the 27th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

7 of the 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center, or all of them as a file.
02

Study summary

The primary purpose of this study is to compare the quality of life (QOL) reported by prostate cancer patients 2 years after treatment with ultra-hypofractionated post-prostatectomy radiation therapy (also known as stereotactic body radiation therapy [SBRT]) versus the self-reported QOL of those treated with moderately hypo-fractionated post-prostatectomy radiation (a current standard of care option).

Read the detailed description

Conventional or moderately hypo-fractionated radiation therapy are the current standard of care treatment options for men receiving post-prostatectomy radiation therapy. These treatment regimens typically span 4-8 weeks, representing a high burden of therapy, which may result in decreased utilization of salvage radiotherapy, the only potentially curable treatment for men with relapsed disease following prostatectomy. Ultra-hypofractionated radiation therapy (also known as stereotactic body radiation therapy [SBRT]) would decrease the total number of treatments to 5, delivered over 2 weeks, which would greatly reduce treatment burden.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Stereotactic Body Radiation Therapy (SBRT)
  • Ultra-hypofractionated Radiation Therapy
  • Post-prostatectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men age ≥ 18 with confirmed prostate cancer after radical prostatectomy with a PSA ≥ 0.1 ng/mL
  • Interval between prostatectomy and planned radiation therapy start date ≥ 6 months
  • ≥ 70
  • Patients with equivocal pelvic lymph nodes on imaging are eligible if the nodes are ≤ 1.5 cm in the short axis (equivocal evidence of disease outside of the pelvis on standard imaging requires documented negative )
  • Ability to complete the EPIC-26 quality of life questionnaire
  • Ability to obtain tissue from radical prostatectomy specimen for review by Michigan Medicine Pathology
  • Ability to understand and the willingness to sign a written .

Exclusion criteria

Exclusion Criteria:

  • Prior history of pelvic radiation therapy
  • History of moderate/severe or active Crohn's disease or ulcerative colitis
  • History of bladder neck or urethral stricture
  • Evidence of distant disease or nodal involvement beyond the common iliac vessels
  • Initiation of androgen deprivation therapy with a LHRH / GnRH agonist or antagonist greater than 6 months prior to enrollment or receipt of any non-LHRH / GnRH agonist or antagonist androgen deprivation or anti-androgen therapy
  • History of another invasive within the previous 3 years except for adequately treated squamous or basal cell skin cancer
  • Any condition that in the opinion of the investigator would preclude participation in this study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (estimated)

Study arms

  • Active comparator
    Moderately Hypo-fractionated Radiation Therapy

    20 fractions of moderately hypofractionated radiation therapy over no more than 5-6 weeks.

    Radiation: Moderately Hypo-fractionated Radiation Therapy

  • Experimental
    Ultra-Hypofractionated Radiation Therapy

    5 fractions of ultra-hypofractionated radiation therapy with at least one day between each treatment over the course of no more than 3-4 weeks

    Radiation: Ultra-hypofractionated radiation therapy

Interventions

  • RadiationUltra-hypofractionated radiation therapy

    34 Gy in 5 fractions to prostate bed, every other day, M-F, \~2 weeks (25 Gy in 5 fractions to pelvic lymph nodes if included)

    Also known as: stereotactic body radiation therapy [SBRT]

  • RadiationModerately Hypo-fractionated Radiation Therapy

    55 Gy in 20 fractions to prostate bed, daily, M-F, 4 weeks (42 Gy in 20 fractions to pelvic lymph nodes if included)

06

What researchers measure

Primary outcomes

  1. Change in patient reported GI and GU quality of life (QOL) at 2-years post-treatment from baseline

    GI and GU QOL assessed with the EPIC-26 questionnaire, bowel and urinary domains. Change scores will be calculated as baseline score subtracted from 2-year score. All patients with EPIC bowel and urinary domain scores will be included in the primary endpoint analysis. The EPIC scoring manual will be followed which requires ≥ 80% of items in a domain to be completed in order to obtain a score for that domain. High bowel score \>96, low bowel score \<= 96, high urinary score \> 84, low urinary score \<=84.

    Time frame: 2-years post-treatment

Secondary outcomes

  1. Patient reported GU quality of life (QOL) up to 60 months

    GU QOL assessed with the EPIC-26 questionnaire, urinary domain; at the end of radiation, 3, 6, 12, and 60 months post-treatment. The EPIC scoring manual will be followed which requires ≥ 80% of items in a domain to be completed in order to obtain a score for that domain. High urinary score \> 84, low urinary score \<=84. A longitudinal analysis incorporating all follow-up time points, will be conducted separately for each domain score.

    Time frame: 60 months post-treatment

  2. Patient reported GI quality of life (QOL) up to 60 months

    GI QOL assessed with the EPIC-26 questionnaire, bowel domain; at the end of radiation, 3, 6, 12, and 60 months post-treatment. The EPIC scoring manual will be followed which requires ≥ 80% of items in a domain to be completed in order to obtain a score for that domain. High bowel score \>96, low bowel score \<= 96. A longitudinal analysis incorporating all follow-up time points, will be conducted separately for each domain score.

    Time frame: 60 months post-treatment

  3. Treatment related toxicity - acute

    Treatment related toxicity (adverse events) assessed with CTCAE version 5.0

    Time frame: ≤ 90 days after treatment completion

  4. Treatment related toxicity - late

    Treatment related toxicity (adverse events) assessed with CTCAE version 5.0

    Time frame: >90 days after treatment completion, up to 5 years

  5. Time to progression

    Time to progression (where progression is defined as the first occurrence of biochemical failure, local failure, regional failure, distant metastasis, start of salvage therapy, or death from prostate cancer)

    Time frame: up to 5 years

  6. Rate of biochemical failure

    Biochemical failure will be assessed using two definitions. Definition one is a PSA ≥ 0.4 ng/mL followed by a second higher value. Definition two is the post-radiation PSA nadir + 2ng/mL

    Time frame: up to 5 years

  7. Local failure, Regional failure, Distant metastases

    Descriptive statistics will be used to describe the number of local, regional and distant metastases. * Local failure is defined as development of a new biopsy-proven mass or prostate specific PET avid mass in the prostate bed after completion of protocol treatment * Regional failure is defined as radiographic evidence of pelvic lymphadenopathy (lymph node size ≥ 1.5 cm in short axis) or PET avid lymph nodes within the pelvis following protocol treatment * Distant metastases is defined as any clinical or radiographic evidence of lymph node, bone, or visceral involvement of prostate cancer

    Time frame: up to 5 years

  8. Prostate cancer specific survival

    Prostate cancer specific survival defined as the duration of time from the start of treatment to death attributable to prostate cancer. Patients who have not died or die of non-prostate cancer related causes will be censored at the date of last known follow-up or date of death, respectively.

    Time frame: up to 5 years

  9. Overall survival

    Overall survival defined as the duration of time from the start of treatment to death from any cause. Patients who have not died will be censored at the date of last known follow-up.

    Time frame: up to 5 years

07

Study locations

1 of 1 sites recruiting
  • University of Michigan Rogel Cancer Center
    Ann Arbor, Michigan 98107, United States
    Recruiting
    • William Jackson, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Nov 2026, 60 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 60 months is close to that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2021
First posted
Sep 9, 2021
StartActual
Nov 12, 2021
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2029
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05038332
Responsible party
Sponsor
First posted
Sep 9, 2021
Start date
Nov 12, 2021
Primary completion
Nov 2026 (estimated)
Completion
Nov 2029 (estimated)
Last update
Jan 16, 2026

Study contacts

Cancer AnswerLine
Contact
CancerAnswerLine@med.umich.edu
1-800-865-1125
William Jackson, M.D.
principal investigator · University of Michigan Rogel Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion